| ORXOF Stock | | | USD 1.08 0.00 0.00% |
CEO
Mr. Nikolaj Sorensen has served as President and Chief Executive Officer of Orexo AB since February 5, 2013. He joined the Company in 2011 and was appointed Chief Commercial Officer on October 1, 2011 since 2013.
| Age | 51 |
| Tenure | 11 years |
| Phone | 46 1 87 80 88 00 |
| Web | https://www.orexo.com |
Sorensen has international commercial experience within the pharmaceutical industry from such companies as Pfizer Inc and Boston Consulting Group . He holds a BS degree and MS degree from Copenhagen Business School.
Orexo AB Management Efficiency
The company has return on total asset
(ROA) of
(0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.
Orexo AB has accumulated 492.3
M in total debt with debt to equity ratio
(D/E) of 1.76, which is about average as compared to similar companies. Orexo AB has a current ratio of 2.01, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orexo AB until it has trouble settling it off, either with new capital or with free cash flow. So, Orexo AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orexo AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orexo to invest in growth at high rates of return. When we think about Orexo AB's use of debt, we should always consider it together with cash and equity.
Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. Orexo Ab is traded on OTC Exchange in the United States. Orexo AB [ORXOF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Orexo AB Leadership Team
Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Orexo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Orexo OTC Stock
Orexo AB financial ratios help investors to determine whether Orexo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orexo with respect to the benefits of owning Orexo AB security.